Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra, Lenalidomide, and Dexamethasone in Early Stage Multiple Myeloma
NCT02492750Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2016
- Primary completion
- Jun 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anakinra in multiple myeloma (MM) (2 arms), sponsored by Mayo Clinic. Primary endpoints: Dose-limiting Toxicity at 28 days, Grade 3+ Adverse Events at 41 months and 1 more. Started Apr 2016; status: completed.
02
Drugs
anakinra
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02492750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02492750.